Whether adjuvant trastuzumab would benefit a woman in the absence of chemotherapy is unknown: proposed studies will explore whether postmenopausal women with estrogen receptor–positive, HER2-positive breast cancer treated with aromatase inhibitors alone benefit from the addition of trastuzumab. The gene discussed is CYP19A1; the disease is breast carcinoma.